44 results on '"Hessamfar, Mojgan"'
Search Results
2. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study—ANRS0001s COV-POPART
- Author
-
Loubet, Paul, Lelievre, Jean-Daniel, François, Alexis, Botelho-Nevers, Elisabeth, Chidiac, Christian, Chirio, David, Dubee, Vincent, Dussol, Bertrand, Galtier, Florence, Hessamfar, Mojgan, Hodaj, Enkelejda, Jaffuel, Sylvain, Lacombe, Karine, Laine, Fabrice, Lefebvre, Maeva, Maakaroun-Vermesse, Zoha, Makinson, Alain, Portefaix, Aurelie, Pourcher, Valerie, Rey, David, Zucman, David, Longobardi, Julie, Bertheau, Mathilde, Tartour, Eric, de Lamballerie, Xavier, Launay, Odile, and Wittkop, Linda
- Published
- 2024
- Full Text
- View/download PDF
3. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies
- Author
-
Trickey, Adam, McGinnis, Kathleen, Gill, M John, Abgrall, Sophie, Berenguer, Juan, Wyen, Christoph, Hessamfar, Mojgan, Reiss, Peter, Kusejko, Katharina, Silverberg, Michael J, Imaz, Arkaitz, Teira, Ramon, d'Arminio Monforte, Antonella, Zangerle, Robert, Guest, Jodie L, Papastamopoulos, Vasileios, Crane, Heidi, Sterling, Timothy R, Grabar, Sophie, Ingle, Suzanne M, and Sterne, Jonathan A C
- Published
- 2024
- Full Text
- View/download PDF
4. Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018–2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
- Author
-
Barger, Diana, Hessamfar, Mojgan, Neau, Didier, Farbos, Sophie, Leleux, Olivier, Cazanave, Charles, Rouanes, Nicolas, Duffau, Pierre, Lazaro, Estibaliz, Rispal, Patrick, Dabis, François, Wittkop, Linda, and Bonnet, Fabrice
- Published
- 2023
- Full Text
- View/download PDF
5. Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV)
- Author
-
Devos, Sophie, Bonnet, Fabrice, Hessamfar, Mojgan, Neau, Didier, Vareil, Marc-Olivier, Leleux, Olivier, Cazanave, Charles, Rouanes, Nicolas, Duffau, Pierre, Lazaro, Estibaliz, Dabis, François, Wittkop, Linda, and Barger, Diana
- Published
- 2023
- Full Text
- View/download PDF
6. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018
- Author
-
Nyamankolly, Elsa, Bellecave, Pantxika, Wittkop, Linda, Le Marec, Fabien, Duffau, Pierre, Lazaro, Estibaliz, Vareil, Marc-Olivier, Tumiotto, Camille, Hessamfar, Mojgan, Cazanave, Charles, Perrier, Adélaïde, Leleux, Olivier, Bonnet, Fabrice, and Neau, Didier
- Published
- 2023
- Full Text
- View/download PDF
7. A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general population
- Author
-
Hémar, Victor, Hessamfar, Mojgan, Neau, Didier, Vareil, Marc-Olivier, Rouanes, Nicolas, Lazaro, Estibaliz, Duffau, Pierre, Cazanave, Charles, Rispal, Patrick, Gaborieau, Valérie, Leleux, Olivier, Wittkop, Linda, Bonnet, Fabrice, and Barger, Diana
- Published
- 2022
- Full Text
- View/download PDF
8. Discrimination of the Veterans Aging Cohort Study Index 2.0 for Predicting Cause-specific Mortality Among Persons With HIV in Europe and North America
- Author
-
Ambia, Julie; https://orcid.org/0000-0001-9883-4561, Ingle, Suzanne M, McGinnis, Kathleen, Pantazis, Nikos, Silverberg, Michael J; https://orcid.org/0000-0001-9322-1395, Wittkop, Linda; https://orcid.org/0000-0003-2403-0960, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Crane, Heidi, van Sighem, Ard, Sarcletti, Mario, Cozzi-Lepri, Alessandro, Domingo, Pere; https://orcid.org/0000-0003-1138-5770, Jarrin, Inma, Wyen, Christoph, Hessamfar, Mojgan, Zhang, Lei, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Berenguer, Juan; https://orcid.org/0000-0001-8541-8200, Sterling, Timothy R; https://orcid.org/0000-0002-4822-6979, Reiss, Peter, Abgrall, Sophie, Gill, M John, Justice, Amy; https://orcid.org/0000-0003-0139-5502, Sterne, Jonathan A C, Trickey, Adam; https://orcid.org/0000-0003-3462-2898, Ambia, Julie; https://orcid.org/0000-0001-9883-4561, Ingle, Suzanne M, McGinnis, Kathleen, Pantazis, Nikos, Silverberg, Michael J; https://orcid.org/0000-0001-9322-1395, Wittkop, Linda; https://orcid.org/0000-0003-2403-0960, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Crane, Heidi, van Sighem, Ard, Sarcletti, Mario, Cozzi-Lepri, Alessandro, Domingo, Pere; https://orcid.org/0000-0003-1138-5770, Jarrin, Inma, Wyen, Christoph, Hessamfar, Mojgan, Zhang, Lei, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Berenguer, Juan; https://orcid.org/0000-0001-8541-8200, Sterling, Timothy R; https://orcid.org/0000-0002-4822-6979, Reiss, Peter, Abgrall, Sophie, Gill, M John, Justice, Amy; https://orcid.org/0000-0003-0139-5502, Sterne, Jonathan A C, and Trickey, Adam; https://orcid.org/0000-0003-3462-2898
- Abstract
BACKGROUND: Predicting cause-specific mortality among people with HIV (PWH) could facilitate targeted care to improve survival. We assessed discrimination of the Veterans Aging Cohort Study (VACS) Index 2.0 in predicting cause-specific mortality among PWH on antiretroviral therapy (ART). METHODS: Using Antiretroviral Therapy Cohort Collaboration data for PWH who initiated ART between 2000 and 2018, VACS Index 2.0 scores (higher scores indicate worse prognosis) were calculated around a randomly selected visit date at least 1 year after ART initiation. Missingness in VACS Index 2.0 variables was addressed through multiple imputation. Cox models estimated associations between VACS Index 2.0 and causes of death, with discrimination evaluated using Harrell's C-statistic. Absolute mortality risk was modelled using flexible parametric survival models. RESULTS: Of 59 741 PWH (mean age: 43 years; 80% male), the mean VACS Index 2.0 at baseline was 41 (range: 0-129). For 2425 deaths over 168 162 person-years follow-up (median: 2.6 years/person), AIDS (n = 455) and non-AIDS-defining cancers (n = 452) were the most common causes. Predicted 5-year mortality for PWH with a mean VACS Index 2.0 score of 38 at baseline was 1% and approximately doubled for every 10-unit increase. The 5-year all-cause mortality C-statistic was .83. Discrimination with the VACS Index 2.0 was highest for deaths resulting from AIDS (0.91), liver-related (0.91), respiratory-related (0.89), non-AIDS infections (0.87), and non-AIDS-defining cancers (0.83), and lowest for suicides/accidental deaths (0.65). CONCLUSIONS: For deaths among PWH, discrimination with the VACS Index 2.0 was highest for deaths with measurable physiological causes and was lowest for suicide/accidental deaths.
- Published
- 2024
9. Enhancing HIV Pre-Exposure Prophylaxis (PrEP) Coverage Through Primary Care Initiation: A French Nationwide Study
- Author
-
Bamouni, Sophie, primary, Billioti de Gage, Sophie, additional, David, Desplas, additional, Valbousquet, Julie, additional, Lamant, Julie, additional, Joseph, Jean-Philippe, additional, Dabis, Francois, additional, Viot, Agnes, additional, Hessamfar, Mojgan, additional, Fakir, Salim, additional, Dray-Spira, Rosemary, additional, and Carles, michel, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Discrimination of the Veterans Aging Cohort Study Index 2.0 for Predicting Cause-specific Mortality Among Persons With HIV in Europe and North America.
- Author
-
Ambia, Julie, Ingle, Suzanne M, McGinnis, Kathleen, Pantazis, Nikos, Silverberg, Michael J, Wittkop, Linda, Kusejko, Katharina, Crane, Heidi, Sighem, Ard van, Sarcletti, Mario, Cozzi-Lepri, Alessandro, Domingo, Pere, Jarrin, Inma, Wyen, Christoph, Hessamfar, Mojgan, Zhang, Lei, Cavassini, Matthias, Berenguer, Juan, Sterling, Timothy R, and Reiss, Peter
- Subjects
AGE discrimination ,SURVIVAL analysis (Biometry) ,DEATH rate ,ANTIRETROVIRAL agents ,MORTALITY - Abstract
Background Predicting cause-specific mortality among people with HIV (PWH) could facilitate targeted care to improve survival. We assessed discrimination of the Veterans Aging Cohort Study (VACS) Index 2.0 in predicting cause-specific mortality among PWH on antiretroviral therapy (ART). Methods Using Antiretroviral Therapy Cohort Collaboration data for PWH who initiated ART between 2000 and 2018, VACS Index 2.0 scores (higher scores indicate worse prognosis) were calculated around a randomly selected visit date at least 1 year after ART initiation. Missingness in VACS Index 2.0 variables was addressed through multiple imputation. Cox models estimated associations between VACS Index 2.0 and causes of death, with discrimination evaluated using Harrell's C-statistic. Absolute mortality risk was modelled using flexible parametric survival models. Results Of 59 741 PWH (mean age: 43 years; 80% male), the mean VACS Index 2.0 at baseline was 41 (range: 0–129). For 2425 deaths over 168 162 person-years follow-up (median: 2.6 years/person), AIDS (n = 455) and non–AIDS-defining cancers (n = 452) were the most common causes. Predicted 5-year mortality for PWH with a mean VACS Index 2.0 score of 38 at baseline was 1% and approximately doubled for every 10-unit increase. The 5-year all-cause mortality C-statistic was.83. Discrimination with the VACS Index 2.0 was highest for deaths resulting from AIDS (0.91), liver-related (0.91), respiratory-related (0.89), non-AIDS infections (0.87), and non–AIDS-defining cancers (0.83), and lowest for suicides/accidental deaths (0.65). Conclusions For deaths among PWH, discrimination with the VACS Index 2.0 was highest for deaths with measurable physiological causes and was lowest for suicide/accidental deaths. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Time to treatment initiation and HIV viral suppression in people diagnosed with HIV-1 during COVID-19 pandemic in ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study)
- Author
-
Ben Farhat, Jihane, primary, Hessamfar, Mojgan, additional, Farbos, Sophie, additional, Desclaux, Arnaud, additional, Dumondin, Gilles, additional, Ferrand, Hélène, additional, Greib, Carine, additional, Castan, Bernard, additional, Rispal, Patrick, additional, Duffau, Pierre, additional, Leleux, Olivier, additional, Perrier, Adélaïde, additional, Wittkop, Linda, additional, Bonnet, Fabrice, additional, and Barger, Diana, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study
- Author
-
Barger, Diana, Hessamfar, Mojgan, Neau, Didier, Vareil, Marc-Olivier, Lazaro, Estibaliz, Duffau, Pierre, Rouanes, Nicolas, Leleux, Olivier, Le Marec, Fabien, Erramouspe, Marie, Wittkop, Linda, Dabis, François, and Bonnet, Fabrice
- Published
- 2020
- Full Text
- View/download PDF
13. Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies
- Author
-
Trickey, Adam, Ingle, Suzanne M, Boyd, Anders, Gill, M John, Grabar, Sophie, Jarrin-Vera, Inmaculada, Obel, Niels, Touloumi, Giota, Zangerle, Robert, Rauch, Andri, Rentsch, Christopher T, Satre, Derek D, Silverberg, Michael J, Bonnet, Fabrice, Guest, Jodie, Burkholder, Greer, Crane, Heidi, Teira, Ramon, Berenguer, Juan, Wyen, Christoph, Abgrall, Sophie, Hessamfar, Mojgan, Reiss, Peter, d'Arminio Monforte, Antonella, McGinnis, Kathleen A, Sterne, Jonathan A C, Wittkop, Linda, Antiretroviral Therapy Cohort Collaboration, NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos), NIH - National Institute of Allergy and Infectious Diseases (NIAID) (Estados Unidos), United States Department of Veterans Affairs, Instituto de Salud Carlos III, Red de Investigación Cooperativa en Investigación en Sida (España), Plan Nacional de I+D+i (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Swiss National Science Foundation, Ministerio de Sanidad (España), Janssen Cilag, Institut National de la Santé et de la Recherche Médicale (Francia), Wellcome Trust, Gilead Sciences (Spain), Ministère de la Santé (Francia), Austrian Agency for Health and Food Safety, Stichting HIV Monitoring, German Center for Infection Research (Alemania), Ministry of Health Welfare and Sport (Países Bajos), National Institute for Health Research (Reino Unido), Alberta Health (Canadá), Agence Nationale de Recherches sur le sida et les hépatites virales (Francia), ViiV Healthcare, and Integrated Clinical Systems
- Subjects
Hepatitis C virus ,Cohort ,HIV ,Mortality ,Alcohol ,Cause-specific - Abstract
Among persons with HIV (PWH), higher alcohol use and having hepatitis C virus (HCV) are separately associated with increased morbidity and mortality. We investigated whether the association between alcohol use and mortality among PWH is modified by HCV. Data were combined from European and North American cohorts of adult PWH who started antiretroviral therapy (ART). Self-reported alcohol use data, collected in diverse ways between cohorts, were converted to grams/day. Eligible PWH started ART during 2001-2017 and were followed from ART initiation for mortality. Interactions between the associations of baseline alcohol use (0, 0.1-20.0, >20.0 g/day) and HCV status were assessed using multivariable Cox models. Of 58,769 PWH, 29,711 (51%), 23,974 (41%) and 5084 (9%) self-reported alcohol use of 0 g/day, 0.1-20.0 g/day, and > 20.0 g/day, respectively, and 4799 (8%) had HCV at baseline. There were 844 deaths in 37,729 person-years and 2755 deaths in 443,121 person-years among those with and without HCV, respectively. Among PWH without HCV, adjusted hazard ratios (aHRs) for mortality were 1.18 (95% CI: 1.08-1.29) for 0.0 g/day and 1.84 (1.62-2.09) for >20.0 g/day compared with 0.1-20.0 g/day. This J-shaped pattern was absent among those with HCV: aHRs were 1.00 (0.86-1.17) for 0.0 g/day and 1.64 (1.33-2.02) for >20.0 g/day compared with 0.1-20.0 g/day (interaction p
- Published
- 2023
14. Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality:A collaboration of cohort studies
- Author
-
Trickey, Adam, Ingle, Suzanne M., Boyd, Anders, Gill, M. John, Grabar, Sophie, Jarrin, Inma, Obel, Niels, Touloumi, Giota, Zangerle, Robert, Rauch, Andri, Rentsch, Christopher T., Satre, Derek D., Silverberg, Michael J., Bonnet, Fabrice, Guest, Jodie, Burkholder, Greer, Crane, Heidi, Teira, Ramon, Berenguer, Juan, Wyen, Christoph, Abgrall, Sophie, Hessamfar, Mojgan, Reiss, Peter, Monforte, Antonella d'Arminio, McGinnis, Kathleen A., Sterne, Jonathan A. C., Wittkop, Linda, Trickey, Adam, Ingle, Suzanne M., Boyd, Anders, Gill, M. John, Grabar, Sophie, Jarrin, Inma, Obel, Niels, Touloumi, Giota, Zangerle, Robert, Rauch, Andri, Rentsch, Christopher T., Satre, Derek D., Silverberg, Michael J., Bonnet, Fabrice, Guest, Jodie, Burkholder, Greer, Crane, Heidi, Teira, Ramon, Berenguer, Juan, Wyen, Christoph, Abgrall, Sophie, Hessamfar, Mojgan, Reiss, Peter, Monforte, Antonella d'Arminio, McGinnis, Kathleen A., Sterne, Jonathan A. C., and Wittkop, Linda
- Abstract
Among persons with HIV (PWH), higher alcohol use and having hepatitis C virus (HCV) are separately associated with increased morbidity and mortality. We investigated whether the association between alcohol use and mortality among PWH is modified by HCV. Data were combined from European and North American cohorts of adult PWH who started antiretroviral therapy (ART). Self-reported alcohol use data, collected in diverse ways between cohorts, were converted to grams/day. Eligible PWH started ART during 2001–2017 and were followed from ART initiation for mortality. Interactions between the associations of baseline alcohol use (0, 0.1–20.0, >20.0 g/day) and HCV status were assessed using multivariable Cox models. Of 58,769 PWH, 29,711 (51%), 23,974 (41%) and 5084 (9%) self-reported alcohol use of 0 g/day, 0.1–20.0 g/day, and > 20.0 g/day, respectively, and 4799 (8%) had HCV at baseline. There were 844 deaths in 37,729 person-years and 2755 deaths in 443,121 person-years among those with and without HCV, respectively. Among PWH without HCV, adjusted hazard ratios (aHRs) for mortality were 1.18 (95% CI: 1.08–1.29) for 0.0 g/day and 1.84 (1.62–2.09) for >20.0 g/day compared with 0.1–20.0 g/day. This J-shaped pattern was absent among those with HCV: aHRs were 1.00 (0.86–1.17) for 0.0 g/day and 1.64 (1.33–2.02) for >20.0 g/day compared with 0.1–20.0 g/day (interaction p <.001). Among PWH without HCV, mortality was higher in both non-drinkers and heavy drinkers compared with moderate alcohol drinkers. Among those with HCV, mortality was higher in heavy drinkers but not non-drinkers, potentially due to differing reasons for not drinking (e.g. illness) between those with and without HCV.
- Published
- 2023
15. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).
- Author
-
Ben Farhat, Jihane, Hessamfar, Mojgan, Farbos, Sophie, Desclaux, Arnaud, Dumondin, Gilles, Ferrand, Hélène, Greib, Carine, Castan, Bernard, Rispal, Patrick, Duffau, Pierre, Leleux, Olivier, Perrier, Adélaïde, Wittkop, Linda, Bonnet, Fabrice, and Barger, Diana
- Abstract
Supplemental Digital Content is Available in the Text. Objectives: The COVID-19 pandemic's impact on initiation and effectiveness of antiretroviral therapy (ART) in people diagnosed with HIV remains unclear. We evaluated critical delays in HIV care in people diagnosed before and during the pandemic in ex-Aquitaine, France. Methods: We considered adults diagnosed with HIV-1 in 2018–2021 and enrolled in the ANRS CO3 AQUIVIH-NA and followed them until October 10, 2022 for those diagnosed during the pandemic (April 01, 2020–December 31, 2021) and until March 31, 2020 for historical controls. We compared their characteristics at inclusion and the median time between diagnosis and ART initiation, ART initiation and viral suppression, and diagnosis and virologic, suppression (effective management). Results: Eighty-three individuals were diagnosed during the pandemic versus 188 during the prepandemic period. Median follow-up was 549 (interquartile range: 329–713) days. Populations were similar in sex, age, HIV acquisition mode, hospital type, and clinical characteristics at diagnosis; however, fewer were foreign-born during the pandemic (15.7% versus 33.5%, P = 0.003). The probability of ART initiation, therapeutic success, and effective management was higher in people living with HIV (PLWH) diagnosed during the pandemic in adjusted analyses (hazard ratio [HR]: 2.0; 95% CI: 1.5 to 2.7; HR: 1.7; 95% CI: 1.2 to 2.3; HR: 1.8; 95% CI: 1.3 to 2.6, respectively). Those diagnosed during the pandemic were 2.3 (95% CI: 1.2 to 4.1) times more likely to be virologically suppressed within six months of diagnosis compared with historical controls. Conclusions: Pandemic-related reorganizations may have resulted in newly diagnosed PLWH being prioritized; however, the lower proportion of foreign-born PLWH diagnosed during the pandemic period, likely because of reduced migration and potential delays in diagnosis, may contribute to these preliminary findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. A case of lenacapavir use for preventing mother-to-child HIV transmission.
- Author
-
Hémar, Victor, Bouchet, Stéphane, Ribeiro, Emmanuel, Prier, Perrine, Elleau, Christophe, Solas, Caroline, Destere, Alexandre, Hessamfar, Mojgan, Tumiotto, Camille, and Bonnet, Fabrice
- Subjects
NON-nucleoside reverse transcriptase inhibitors ,PREGNANT women ,PREGNANCY outcomes ,HIV infections ,VERTICAL transmission (Communicable diseases) ,PREGNANCY - Abstract
The article discusses the use of lenacapavir, an HIV capsid inhibitor, in preventing mother-to-child HIV transmission in a 31-year-old woman with poor adherence to oral antiretroviral therapy during pregnancy. Despite initial success, the patient developed resistance to lenacapavir due to non-adherence, highlighting the importance of strict treatment adherence. The study demonstrates transplacental transfer of lenacapavir without toxicity to the newborn, suggesting its potential as a long-acting treatment option for pregnant women with poor adherence to oral ART. Further research is needed to assess the safety and efficacy of lenacapavir in pregnant and lactating individuals. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
17. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response
- Author
-
Krastinova, Evguenia, Bani-Sadr, Firouzé, Fromentin, Delphine, Goujard, Cécile, Hessamfar, Mojgan, Yazdanpanah, Yazdan, Pol, Stanislas, Cacoub, Patrice, Perronne, Christian, and Carrat, Fabrice
- Published
- 2014
- Full Text
- View/download PDF
18. Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
- Author
-
Camou, Fabrice, primary, Issa, Nahéma, additional, Hessamfar, Mojgan, additional, Guisset, Olivier, additional, Mourissoux, Gaëlle, additional, Pedeboscq, Stéphane, additional, Minot, Aimée, additional, and Bonnet, Fabrice, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Prevalence of Mycoplasma genitalium Among HIV-Infected Women, Agence Nationale de Recherches sur le SIDA et les hépatites virales CO3 Aquitaine Cohort, France
- Author
-
Cazanave, Charles, Lawson-Ayayi, Sylvie, Hessamfar, Mojgan, Morlat, Philippe, Neau, Didier, Dupon, Michel, Dabis, François, de Barbeyrac, Bertille, Bébéar, Cécile, and Pereyre, Sabine
- Published
- 2013
20. High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection
- Author
-
Ngo Bell, Elisabeth Carolle, Vandenhende, Marie-Anne, Caldato, Sabrina, Saunier, Aurélie, Bellecave, Pantxika, Tumiotto, Camille, Avettand-Fenoel, Véronique, Hessamfar, Mojgan, Morlat, Philippe, and Bonnet, Fabrice
- Published
- 2017
- Full Text
- View/download PDF
21. Effect of Cytomegalovirus-Induced Immune Response, Self Antigen—Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1—Infected Patients: The ANRS CO3 Aquitaine Cohort
- Author
-
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine, Wittkop, Linda, Bitard, Juliette, Lazaro, Estibaliz, Neau, Didier, Bonnet, Fabrice, Mercie, Patrick, Dupon, Michel, Hessamfar, Mojgan, Ventura, Michel, Malvy, Denis, Dabis, François, Pellegrin, Jean-Luc, Moreau, Jean-François, Thiébaut, Rodolphe, and Pellegrin, Isabelle
- Published
- 2013
- Full Text
- View/download PDF
22. A highly virulent variant of HIV-1 circulating in the Netherlands
- Author
-
Wymant, Chris, Bezemer, Daniela, Blanquart, François, Ferretti, Luca, Gall, Astrid, Hall, Matthew, Golubchik, Tanya, Bakker, Margreet, Ong, Swee Hoe, Zhao, Lele, Bonsall, David, de Cesare, Mariateresa, MacIntyre-Cockett, George, Abeler-Dörner, Lucie, Albert, Jan, Bannert, Norbert, Fellay, Jacques, Grabowski, M Kate, Gunsenheimer-Bartmeyer, Barbara, Günthard, Huldrych F, Kivelä, Pia, Kouyos, Roger D, Laeyendecker, Oliver, Meyer, Laurence, Porter, Kholoud, Ristola, Matti, van Sighem, Ard, Berkhout, Ben, Kellam, Paul, Cornelissen, Marion, Reiss, Peter, Fraser, Christophe, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, D L, Bucher, H C, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, C A, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, H H, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B Martinez, Marzolini, C, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schöni-Affolter, F, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Weber, R, Yerly, S, van der Valk, M, Geerlings, S E, Goorhuis, A, Hovius, J W, Lempkes, B, Nellen, F J B, van der Poll, T, Prins, J M, Reiss, P, van Vugt, M, Wiersinga, W J, Wit, F W M N, van Duinen, M, van Eden, J, Hazenberg, A, van Hes, A M H, Pijnappel, F J J, Smalhout, S Y, Weijsenfeld, A M, Jurriaans, S, Back, N K T, Zaaijer, H L, Berkhout, B, Cornelissen, M T E, Schinkel, C J, Wolthers, K C, Peters, E J G, van Agtmael, M A, Autar, R S, Bomers, M, Sigaloff, K C E, Heitmuller, M, Laan, L M, Ang, C W, van Houdt, R, Jonges, M, Kuijpers, T W, Pajkrt, D, Scherpbier, H J, de Boer, C, van der Plas, A, van den Berge, M, Stegeman, A, Baas, S, Hage de Looff, L, Buiting, A, Reuwer, A, Veenemans, J, Wintermans, B, Pronk, M J H, Ammerlaan, H S M, van den Bersselaar, D N J, de Munnik, E S, Deiman, B, Jansz, A R, Scharnhorst, V, Tjhie, J, Wegdam, M C A, van Eeden, A, Nellen, J, Brokking, W, Elsenburg, L J M, Nobel, H, van Kasteren, M E E, Berrevoets, M A H, Brouwer, A E, Adams, A, van Erve, R, de Kruijf-van de Wiel, B A F M, Keelan-Phaf, S, van der Ven, B, Buiting, A G M, Murck, J L, de Vries-Sluijs, T E M S, Bax, H I, van Gorp, E C M, de Jong-Peltenburg, N C, de Mendonç A Melo, M, van Nood, E, Nouwen, J L, Rijnders, B J A, Rokx, C, Schurink, C A M, Slobbe, L, Verbon, A, Bassant, N, van Beek, J E A, Vriesde, M, van Zonneveld, L M, de Groot, J, Boucher, C A B, Koopmans, M P G, van Kampen, J J A, Fraaij, P L A, van Rossum, A M C, Vermont, C L, van der Knaap, L C, Visser, E, Branger, J, Douma, R A, Cents-Bosma, A S, Duijf-van de Ven, C J H M, Schippers, E F, van Nieuwkoop, C, van Ijperen, J M, Geilings, J, van der Hut, G, van Burgel, N D, Leyten, E M S, Gelinck, L B S, Mollema, F, Davids-Veldhuis, S, Tearno, C, Wildenbeest, G S, Heikens, E, Groeneveld, P H P, Bouwhuis, J W, Lammers, A J J, Kraan, S, van Hulzen, A G W, Kruiper, M S M, van der Bliek, G L, Bor, P C J, Debast, S B, Wagenvoort, G H J, Kroon, F P, de Boer, M G J, Jolink, H, Lambregts, M M C, Roukens, A H E, Scheper, H, Dorama, W, van Holten, N, Claas, E C J, Wessels, E, den Hollander, J G, El Moussaoui, R, Pogany, K, Smit, J V, Struik-Kalkman, D, van Niekerk, T, Pontesilli, O, Lowe, S H, Oude Lashof, A M L, Posthouwer, D, van Wolfswinkel, M E, Ackens, R P, Burgers, K, Schippers, J, Weijenberg-Maes, B, van Loo, I H M, Havenith, T R A, van Vonderen, M G A, Kampschreur, L M, Faber, S, Steeman-Bouma, R, Al Moujahid, A, Kootstra, G J, Delsing, C E, van der Burg-van de Plas, M, Scheiberlich, L, Kortmann, W, van Twillert, G, Renckens, R, Ruiter-Pronk, D, van Truijen-Oud, F A, Cohen Stuart, J W T, Jansen, E R, Hoogewerf, M, Rozemeijer, W, van der Reijden, W A, Sinnige, J C, Brinkman, K, van den Berk, G E L, Blok, W L, Lettinga, K D, de Regt, M, Schouten, W E M, Stalenhoef, J E, Veenstra, J, Vrouenraets, S M E, Blaauw, H, Geerders, G F, Kleene, M J, Kok, M, Knapen, M, van der Meché, I B, Mulder-Seeleman, E, Toonen, A J M, Wijnands, S, Wttewaal, E, Kwa, D, van Crevel, R, van Aerde, K, Dofferhoff, A S M, Henriet, S S V, Ter Hofstede, H J M, Hoogerwerf, J, Keuter, M, Richel, O, Albers, M, Grintjes-Huisman, K J T, de Haan, M, Marneef, M, Strik-Albers, R, Rahamat-Langendoen, J, Stelma, F F, Burger, D, Gisolf, E H, Hassing, R J, Claassen, M, Ter Beest, G, van Bentum, P H M, Langebeek, N, Tiemessen, R, Swanink, C M A, van Lelyveld, S F L, Soetekouw, R, van der Prijt, L M M, van der Swaluw, J, Bermon, N, Jansen, R, Herpers, B L, Veenendaal, D, Verhagen, D W M, Lauw, F N, van Broekhuizen, M C, van Wijk, M, Bierman, W F W, Bakker, M, Kleinnijenhuis, J, Kloeze, E, Middel, A, Postma, D F, Schölvinck, E H, Stienstra, Y, Verhage, A R, Wouthuyzen-Bakker, M, Boonstra, A, de Groot-de Jonge, H, van der Meulen, P A, de Weerd, D A, Niesters, H G M, van Leer-Buter, C C, Knoester, M, Hoepelman, A I M, Arends, J E, Barth, R E, Bruns, A H W, Ellerbroek, P M, Mudrikova, T, Oosterheert, J J, Schadd, E M, van Welzen, B J, Aarsman, K, Griffioen-van Santen, B M G, de Kroon, I, van Berkel, M, van Rooijen, C S A M, Schuurman, R, Verduyn-Lunel, F, Wensing, A M J, Bont, L J, Geelen, S P M, Loeffen, Y G T, Wolfs, T F W, Nauta, N, Rooijakkers, E O W, Holtsema, H, Voigt, R, van de Wetering, D, Alberto, A, van der Meer, I, Rosingh, A, Halaby, T, Zaheri, S, Boyd, A C, Bezemer, D O, van Sighem, A I, Smit, C, Hillebregt, M, de Jong, A, Woudstra, T, Bergsma, D, Meijering, R, van de Sande, L, Rutkens, T, van der Vliet, S, de Groot, L, van den Akker, M, Bakker, Y, El Berkaoui, A, Bezemer, M, Brétin, N, Djoechro, E, Groters, M, Kruijne, E, Lelivelt, K J, Lodewijk, C, Lucas, E, Munjishvili, L, Paling, F, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Schoorl, M, Schnörr, P, Scheigrond, A, Tuijn, E, Veenenberg, L, Visser, K M, Witte, E C, Van Frankenhuijsen, Maartje, Allegre, Thierry, Makhloufi, Djamila, Livrozet, Jean-Michel, Chiarello, Pierre, Godinot, Mathieu, Brunel-Dalmas, Florence, Gibert, Sylvie, Trepo, Christian, Peyramond, Dominique, Miailhes, Patrick, Koffi, Joseph, Thoirain, Valérie, Brochier, Corinne, Baudry, Thomas, Pailhes, Sylvie, Lafeuillade, Alain, Philip, Gisèle, Hittinger, Gilles, Assi, Assi, Lambry, Véronique, Rosenthal, Eric, Naqvi, Alissa, Dunais, Brigitte, Cua, Eric, Pradier, Christian, Durant, Jacques, Joulie, Aline, Quinsat, Denis, Tempesta, Serge, Ravaux, Isabelle, Martin, Isabelle Poizot, Faucher, Olivia, Cloarec, Nicolas, Champagne, Hélène, Pichancourt, Gilles, Morlat, Philippe, Pistone, Thierry, Bonnet, Fabrice, Mercie, Patrick, Faure, Isabelle, Hessamfar, Mojgan, Malvy, Denis, Lacoste, Denis, Pertusa, Marie-Carmen, Vandenhende, Marie-Anne, Bernard, Noëlle, Paccalin, François, Martell, Cédric, Roger-Schmelz, Julien, Receveur, Marie-Catherine, Duffau, Pierre, Dondia, Denis, Ribeiro, Emmanuel, Caltado, Sabrina, Neau, Didier, Dupont, Michel, Dutronc, Hervé, Dauchy, Frédéric, Cazanave, Charles, Vareil, Marc-Olivier, Wirth, Gaétane, Le Puil, Séverine, Pellegrin, Jean-Luc, Raymond, Isabelle, Viallard, Jean-François, Chaigne de Lalande, Severin, Garipuy, Daniel, Delobel, Pierre, Obadia, Martine, Cuzin, Lise, Alvarez, Muriel, Biezunski, Noemie, Porte, Lydie, Massip, Patrice, Debard, Alexa, Balsarin, Florence, Lagarrigue, Myriam, Prevoteau du Clary, François, Aquilina, Christian, Reynes, Jacques, Baillat, Vincent, Merle, Corinne, Lemoing, Vincent, Atoui, Nadine, Makinson, Alain, Jacquet, Jean Marc, Psomas, Christina, Tramoni, Christine, Aumaitre, Hugues, Saada, Mathieu, Medus, Marie, Malet, Martine, Eden, Aurélia, Neuville, Ségolène, Ferreyra, Milagros, Sotto, Albert, Barbuat, Claudine, Rouanet, Isabelle, Leureillard, Didier, Mauboussin, Jean-Marc, Lechiche, Catherine, Donsesco, Régine, Cabie, André, Abel, Sylvie, Pierre-Francois, Sandrine, Batala, Anne-Sophie, Cerland, Christophe, Rangom, Camille, Theresine, Nadine, Hoen, Bruno, Lamaury, Isabelle, Fabre, Isabelle, Schepers, Kinda, Curlier, Elodie, Ouissa, Rachida, Gaud, Catherine, Ricaud, Carole, Rodet, Roland, Wartel, Guillaume, Sautron, Carmele, Beck-Wirth, Geneviève, Michel, Catherine, Beck, Charles, Halna, Jean-Michel, Kowalczyk, Jakub, Benomar, Meryem, Drobacheff-Thiebaut, Christine, Chirouze, Catherine, Faucher, Jean-François, Parcelier, François, Foltzer, Adeline, Haffner-Mauvais, Cécile, Hustache Mathieu, Mathieu, Proust, Aurélie, Piroth, Lionel, Chavanet, Pascal, Duong, Michel, Buisson, Marielle, Waldner, Anne, Mahy, Sophie, Gohier, Sandrine, Croisier, Delphine, May, Thierry, Delestan, Mikael, Andre, Marie, Zadeh, Mahsa Mohseni, Martinot, Martin, Rosolen, Béatrice, Pachart, Anne, Martha, Benoît, Jeunet, Noëlle, Rey, David, Cheneau, Christine, Partisani, Maria, Priester, Michèle, Bernard-Henry, Claudine, Batard, Marie-Laure, Fischer, Patricia, Berger, Jean-Luc, Kmiec, Isabelle, Robineau, Olivier, Huleux, Thomas, Ajana, Faïza, Alcaraz, Isabelle, Allienne, Christophe, Baclet, Véronique, Meybeck, Agnès, Valette, Michel, Viget, Nathalie, Aissi, Emmanuelle, Biekre, Raphael, Cornavin, Pauline, Merrien, Dominique, Seghezzi, Jean-Christophe, Machado, Moise, Diab, Georges, Raffi, François, Bonnet, Bénédicte, Allavena, Clotilde, Grossi, Olivier, Reliquet, Véronique, Billaud, Eric, Brunet, Cecile, Bouchez, Sabelline, Morineau-Le Houssine, Pascale, Sauser, Fabienne, Boutoille, David, Besnier, Michel, Hue, Hervé, Hall, Nolwenn, Brosseau, Delphine, Souala, Faouzi, Michelet, Christian, Tattevin, Pierre, Arvieux, Cédric, Revest, Matthieu, Leroy, Helene, Chapplain, Jean-Marc, Dupont, Matthieu, Fily, Fabien, Patra-Delo, Solène, Lefeuvre, Céline, Bernard, Louis, Bastides, Frédéric, Nau, Pascale, Verdon, Renaud, de la Blanchardiere, Arnaud, Martin, Anne, Feret, Philippe, Geffray, Loïk, Daniel, Corinne, Rohan, Jennifer, Fialaire, Pascale, Chennebault, Jean Marie, Rabier, Valérie, Abgueguen, Pierre, Rehaiem, Sami, Luycx, Odile, Niault, Mathilde, Moreau, Philippe, Poinsignon, Yves, Goussef, Marie, Mouton-Rioux, Virginie, Houlbert, Dominique, Alvarez-Huve, Sandrine, Barbe, Frédérique, Haret, Sophie, Perre, Philippe, Leantez-Nainville, Sophie, Esnault, Jean-Luc, Guimard, Thomas, Suaud, Isabelle, Girard, Jean-Jacques, Simonet, Véronique, Debab, Yasmine, Schmit, Jean-Luc, Jacomet, Christine, Weinberck, Pierre, Genet, Claire, Pinet, Pauline, Ducroix, Sophie, Durox, Hélène, Denes, Éric, Abraham, Bruno, Gourdon, Florence, Antoniotti, Odile, Molina, Jean-Michel, Ferret, Samuel, Lascoux-Combe, Caroline, Lafaurie, Matthieu, Colin de Verdiere, Nathalie, Ponscarme, Diane, De Castro, Nathalie, Aslan, Alexandre, Rozenbaum, Willy, Pintado, Claire, Clavel, François, Taulera, Olivier, Gatey, Caroline, Munier, Anne-Lise, Gazaigne, Sandrine, Penot, Pauline, Conort, Guillaume, Lerolle, Nathalie, Leplatois, Anne, Balausine, Stéphanie, Delgado, Jeannine, Timsit, Julie, Tabet, Magda, Gerard, Laurence, Girard, Pierre-Marie, Picard, Odile, Tredup, Jürgen, Bollens, Diane, Valin, Nadia, Campa, Pauline, Bottero, Julie, Lefebvre, Benedicte, Tourneur, Muriel, Fonquernie, Laurent, Wemmert, Charlotte, Lagneau, Jean-Luc, Yazdanpanah, Yazdan, Phung, Bao, Pinto, Adriana, Vallois, Dorothée, Cabras, Ornella, Louni, Françoise, Pialoux, Gilles, Lyavanc, Thomas, Berrebi, Valérie, Chas, Julie, Lenagat, Sophie, Rami, Agathe, Diemer, Myriam, Parrinello, Maguy, Depond, Audrey, Salmon, Dominique, Guillevin, Loïc, Tahi, Tassadit, Belarbi, Linda, Loulergue, Pierre, Zak Dit Zbar, Olivier, Launay, Odile, Silbermann, Benjamin, Leport, Catherine, Alagna, Laura, Pietri, Marie-Pierre, Simon, Anne, Bonmarchand, Manuela, Amirat, Naouel, Pichon, François, Kirstetter, Myriam, Katlama, Christine, Valantin, Marc Antoine, Tubiana, Roland, Caby, Fabienne, Schneider, Luminita, Ktorza, Nadine, Calin, Ruxandra, Merlet, Audrey, Ben Abdallah, Saadia, Weiss, Laurence, Buisson, Martin, Batisse, Dominique, Karmochine, Marina, Pavie, Juliette, Minozzi, Catherine, Jayle, Didier, Castel, Philippe, Derouineau, Jean, Kousignan, Pascale, Eliazevitch, Murielle, Pierre, Isabelle, Collias, Lio, Viard, Jean-Paul, Gilquin, Jacques, Sobel, Alain, Slama, Laurence, Ghosn, Jade, Hadacek, Blanka, Thu-Huyn, Nugyen, Nait-Ighil, Lella, Cros, Agnes, Maignan, Aline, Duvivier, Claudine, Consigny, Paul Henri, Lanternier, Fanny, Shoai-Tehrani, Michka, Touam, Fatima, Jerbi, Saadia, Bodard, Loïc, Jung, Corinne, Goujard, Cécile, Quertainmont, Yann, Duracinsky, Martin, Segeral, Olivier, Blanc, Arnaud, Peretti, Delphine, Cheret, Antoine, Chantalat, Christelle, Dulucq, Marie Josée, Levy, Yves, Lelievre, Jean Daniel, Lascaux, Anne Sophie, Dumont, Cécile, Boue, François, Chambrin, Véronique, Abgrall, Sophie, Kansau, Imad, Raho-Moussa, Mariem, De Truchis, Pierre, Dinh, Aurélien, Davido, Benjamin, Marigot, Dhiba, Berthe, Huguette, Devidas, Alain, Chevojon, Pierre, Chabrol, Amélie, Agher, Nouara, Lemercier, Yvon, Chaix, Fabrice, Turpault, Isabelle, Bouchaud, Olivier, Honore, Patricia, Rouveix, Elisabeth, Reimann, Evelyne, Belan, Alix Greder, Godin Collet, Claire, Souak, Safia, Mortier, Emmanuel, Bloch, Martine, Simonpoli, Anne-Marie, Manceron, Véronique, Cahitte, Isabelle, Hiraux, Emmanuel, Lafon, Erik, Cordonnier, François, Zeng, Ai-Feng, Zucman, David, Majerholc, Catherine, Bornarel, Dominique, Uludag, Agnès, Gellen-Dautremer, Justine, Lefort, Agnès, Bazin, Christine, Daneluzzi, Vincent, Gerbe, Juliette, Jeantils, Vincent, Coupard, Mélissa, Patey, Olivier, Bantsimba, Jonas, Delllion, Sophie, Paz, Pauline Caraux, Cazenave, Benoit, Richier, Laurent, Garrait, Valérie, Delacroix, Isabelle, Elharrar, Brigitte, Vittecoq, Daniel, Bolliot, Claudine, Lepretre, Annie, Genet, Philippe, Masse, Virginie, Perrone, Véronique, Boussard, Jean-Luc, Chardon, Patricia, Froguel, Eric, Simon, Philippe, Tassi, Sylvie, Avettand Fenoel, Véronique, Barin, Francis, Bourgeois, Christine, Cardon, Fanny, Chaix, Marie-Laure, Delfraissy, Jean François, Essat, Asma, Fischer, Hugues, Lecuroux, Camille, Petrov-Sanchez, Ventzislava, Rouzioux, Christine, Saez-Cirion, Asier, Seng, Rémonie, Kuldanek, Kristin, Mullaney, Scott, Young, Carmel, Zucchetti, Antonella, Bevan, Margaret-Ann, McKernan, Sinead, Wandolo, Emily, Richardson, Celia, Youssef, Elaney, Green, Pippa, Faulkner, Sue, Faville, Rebecca, Herman, Sandra, Care, Christine, Blackman, Helen, Bellenger, Katharine, Fairbrother, Keith, Phillips, Andrew, Babiker, Abdel, Delpech, Valerie, Fidler, S, Clarke, Mindy, Fox, Julie, Gilson, R, Goldberg, David, Hawkins, David, Johnson, Anne, Johnson, Margaret, McLean, Ken, Nastouli, Eleni, Post, Frank, Kennedy, N, Pritchard, J, Andrady, U, Rajda, N, Donnelly, C, McKernan, S, Drake, S, Gilleran, G, White, D, Ross, J, Harding, J, Faville, R, Sweeney, J, Flegg, P, Toomer, S, Wilding, H, Woodward, R, Dean, G, Richardson, C, Perry, N, Gompels, M, Jennings, L, Bansaal, D, Browing, M, Connolly, L, Stanley, B, Estreich, S, Magdy, A, O'Mahony, C, Fraser, P, Jebakumar, S P R, David, L, Mette, R, Summerfield, H, Evans, M, White, C, Robertson, R, Lean, C, Morris, S, Winter, A, Faulkner, S, Goorney, B, Howard, L, Fairley, I, Stemp, C, Short, L, Gomez, M, Young, F, Roberts, M, Green, S, Sivakumar, K, Minton, J, Siminoni, A, Calderwood, J, Greenhough, D, DeSouza, C, Muthern, Lisa, Orkin, C, Murphy, S, Truvedi, M, McLean, K, Hawkins, D, Higgs, C, Moyes, A, Antonucci, S, McCormack, S, Lynn, W, Bevan, M, Fox, J, Teague, A, Anderson, J, Mguni, S, Post, F, Campbell, L, Mazhude, C, Russell, H, Carrick, G, Ainsworth, J, Waters, A, Byrne, P, Johnson, M, Kuldanek, K, Mullaney, S, Lawlor, V, Melville, R, Sukthankar, A, Thorpe, S, Murphy, C, Wilkins, E, Ahmad, S, Green, P, Tayal, S, Ong, E, Meaden, J, Riddell, L, Loay, D, Peacock, K, Blackman, H, Harindra, V, Saeed, A M, Allen, S, Natarajan, U, Williams, O, Lacey, H, Care, C, Bowman, C, Herman, S, Devendra, S V, Wither, J, Bridgwood, A, Singh, G, Bushby, S, Kellock, D, Young, S, Rooney, G, Snart, B, Currie, J, Fitzgerald, M, Arumainayyagam, J, Chandramani, S, Rajamanoharan, S, Robinson, T, Taylor, B, Brewer, C, Mayr, Christoph, Schmidt, Wolfgang, Speidel, Andrea, Strohbach, Frank, Arastéh, Keikawus, Cordes, Christiane, Stündel, Manfred, Claus, Jörg, Baumgarten, Axel, Carganico, Andreas, Ingiliz, Patrick, Dupke, Stephan, Freiwald, Matthias, Rausch, Michael, Moll, Arend, Schleehauf, Dorothea, Hintsche, Bettina, Klausen, Gerd, Jessen, Heiko, Jessen, Arne, Köppe, Siegfried, Kreckel, Peter, Schranz, Dietmar, Fischer, Klaus, Schulbin, Hubert, Speer, Miriam, Glaunsinger, Tobias, Wicke, Thomas, Bieniek, Bernhard, Hillenbrand, Heribert, Schlote, Frank, Lauenroth-Mai, Elke, Schuler, Christoph, Schürmann, Dirk, Wesselmann, Hans, Brockmeyer, Norbert, Gehring, Peter, Schmalöer, Dirk, Hower, Martin, Spornraft-Ragaller, Petra, Häussinger, Dieter, Reuter, Stefan, Esser, Stefan, Markus, Rudolf, Kreft, Burkhard, Berzow, Dirk, Christl, Andreas, Meyer, Andreas, Plettenberg, Andreas, Stoehr, Albrecht, Graefe, Katrin, Lorenzen, Thore, Adam, Axel, Schewe, Knut, Weitner, Lutwin, Fenske, Stefan, Hansen, Stefan, Stellbrink, Hans-Jürgen, Wiemer, Dorothea, Hertling, Sandra, Schmidt, Reinhold, Arbter, Peter, Claus, Bernd, Galle, Peter, Jäger, Hans, Jä Gel-Guedes, Eva, Postel, Nils, Fröschl, Monika, Spinner, Christoph, Bogner, Johannes, Salzberger, Bernd, Schölmerich, Jürgen, Audebert, Franz, Marquardt, Ties, Schaffert, Andreas, Schnaitmann, Eiko, Trein, Andreas, Frietsch, Bernhard, Müller, Marcus, Ulmer, Albrecht, Detering-Hübner, Barbara, Kern, Peter, Schubert, Franz, Dehn, Günther, Schreiber, Maria, Güler, Cengiz, Schmidt, Daniel, Meixenberger, Karolin, Medical Microbiology & Infectious Diseases, Internal Medicine, Virology, Pediatrics, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Global Health, Infectious diseases, APH - Aging & Later Life, Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Internal medicine, VU University medical center, Surgery, AMS - Rehabilitation & Development, APH - Quality of Care, Psychiatry, Pediatric surgery, Neurology, Public and occupational health, APH - Mental Health, Pathology, Cardiology, ACS - Heart failure & arrhythmias, Anesthesiology, IOO, Rehabilitation medicine, Obstetrics and gynaecology, General practice, Gastroenterology and hepatology, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Medical oncology laboratory, Hematology, Epidemiology and Data Science, Physiology, Microbes in Health and Disease (MHD), University of Oxford, Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), European Bioinformatics Institute [Hinxton] (EMBL-EBI), EMBL Heidelberg, Amsterdam UMC - Amsterdam University Medical Center, The Wellcome Trust Sanger Institute [Cambridge], Karolinska Institutet [Stockholm], Robert Koch Institute [Berlin] (RKI), Ecole Polytechnique Fédérale de Lausanne (EPFL), Johns Hopkins University (JHU), Universität Zürich [Zürich] = University of Zurich (UZH), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University College of London [London] (UCL), Kymab Ltd, Cambridge, England, Institut Pasteur [Paris] (IP), This study was funded by ERC Advanced Grant PBDR-339251 and a Li Ka Shing Foundation grant, both awarded to C.F. The ATHENA Cohort is managed by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment., We thank K. Fransen and G. Vanham for help with the Belgian data, O. Ratmann for help in identifying the Dutch clusters, K. Kusejko for testing for additional VB individuals in the SHCS, B. Foley for help with genome sharing, B. Dearlove and L. Thomson for help with software, and J. Herbeck and three other reviewers for helpful suggestions., Contributors and affiliations are listed in the supplementary materials., Department of Medicine, University of Helsinki, Infektiosairauksien yksikkö, HUS Inflammation Center, and Clinicum
- Subjects
Adult ,Male ,HIV-1/genetics ,Genotype ,Anti-HIV Agents ,Evolution ,[SDV]Life Sciences [q-bio] ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,HIV Infections/drug therapy ,selection ,HIV Infections ,Genome, Viral ,heritability ,epidemic ,human-immunodeficiency-virus ,Evolution, Molecular ,SDG 3 - Good Health and Well-being ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Humans ,Viral ,Phylogeny ,Netherlands ,Multidisciplinary ,Genome ,model ,Virulence ,transmission ,Molecular ,setpoint viral load ,reverse-transcriptase ,dynamics ,Viral Load ,CD4 Lymphocyte Count ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,3121 General medicine, internal medicine and other clinical medicine ,Anti-HIV Agents/therapeutic use ,Mutation ,HIV-1 ,Female ,progression - Abstract
Comment in Does HIV-1 virulence matter in the ART era? Lewitus E, Rolland M. Med (N Y). 2022 Apr 8;3(4):217-219. doi: 10.1016/j.medj.2022.03.003. PMID: 35590149; International audience; We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log 10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV—CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences—is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
- Published
- 2022
- Full Text
- View/download PDF
23. Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7
- Author
-
Lajaunie, Rébecca, Mainardi, Ilaria, Gasnault, Jacques, Rousseau, Vanessa, Tarantino, Andrea, Sommet, Agnès, Cinque, Paola, Martin-Blondel, Guillaume, Debard, Alexa, Delobel, Pierre, Pansu, Nathalie, Gollion, Cédric, Benaiteau, Marie, Jacomet, Christine, Mélé, Nicolas, Moulignier, Antoine, Suarez, Felipe, Ruch, Yvon, Tranchant, Christine, Lemaignen, Adrien, Langner-Lemercier, Sophie, Buzele, Rodolphe, Guffroy, Aurelien, Moluçon-Chabrot, Cécile, Tattevin, Pierre, Melica, Giovanna, Badiu, Carmen‐ionela, Cheraud-Bonfort, Chrystel, Salmon, Anne, Alstadhaug, Karl Bjornar, Kuhlmann, F. Matthew, Gorza, Lucas, Wang, Adrien, Wille, Heidi, Curlier, Elodie, Hessamfar, Mojgan, Valour, Florent, Perpoint, Thomas, Koralnik, Igor, Decaestecker, Kevin, Vindrios, William, Guilbert, Anne, Boulesteix, Jean Marc, Verdière, Sylvie Colin De, Roux, Antoine, Patel, Amila, Fabian, Michelle, Harel, Asaff, Wyplosz, Benjamin, Ader, Florence, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), San Raffaele Scientific Institute, Vita-Salute San Raffaele University and Center for Translational Genomics and Bioinformatics, Immunologie intégrative des tumeurs (UMR 1186), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and This study was not funded.
- Subjects
MESH: Humans ,Interleukin-7 ,MESH: Leukoencephalopathy, Progressive Multifocal ,MESH: JC Virus ,Leukoencephalopathy, Progressive Multifocal ,MESH: Retrospective Studies ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,HIV Infections ,MESH: HIV Infections ,JC Virus ,MESH: Interleukin-7 ,Neurology ,Hematologic Neoplasms ,Humans ,Neurology (clinical) ,MESH: Hematologic Neoplasms ,Retrospective Studies - Abstract
International audience; Objective: Restoring anti-JC virus (JCV) immunity is the only treatment of progressive multifocal leukoencephalopathy (PML). Interleukin-7 is a cytokine that increases number and function of T cells. We analyzed a population of PML patients who received recombinant human IL-7 (rhIL-7) to estimate survival and its determinants.Methods: After exclusion of patients with missing data or receiving other immunotherapies, findings from 64 patients with proven PML who received rhIL-7 between 2007 and 2020 were retrospectively analyzed. Logistic regression was used to analyze variables associated with one-year survival.Results: Underlying conditions were HIV/AIDS (n = 27, 42%), hematological malignancies (n = 16, 25%), primary immunodeficiencies (n = 13, 20%), solid organ transplantation (n = 4, 6%) and chronic inflammatory diseases (n = 4, 6%). One-year survival was 54.7% and did not differ by underlying condition. Survival was not associated with baseline characteristics, but with a >50% increase in blood lymphocytes (OR 4.1, 95%CI 1.2-14.9) and CD4+ T cells (OR 5.9, 95%CI 1.7-23.3), and a > 1 log copies/mL decrease in cerebrospinal fluid JCV DNA (OR 7.6, 95%CI 1.6-56.1) during the first month after rhIL-7 initiation. Side effects were mainly local and flu-like symptoms (n = 8, 12.5%) and PML-immune reconstitution inflammatory syndrome (IRIS) (n = 5, 8%).Interpretation: In this non-controlled retrospective study, survival did not differ from that expected in HIV/AIDS patients, but might have been improved in those with hematological malignancies, primary immunodeficiencies and transplant recipients. RhIL-7 might have contributed to the increase in blood lymphocytes and decrease in CSF JCV replication that were associated with better survival. ANN NEUROL 2022;91:496-505.
- Published
- 2021
- Full Text
- View/download PDF
24. Risk of superinfection in critically ill COVID-19 patients receiving tocilizumab plus dexamethasone
- Author
-
CAMOU, FABRICE, primary, ISSA, NAHEMA, additional, HESSAMFAR, MOJGAN, additional, GUISSET, OLIVIER, additional, MOURISSOUX, GAELLE, additional, PEDEBOSCQ, STEPHANE, additional, MINOT, AIMEE, additional, and BONNET, FABRICE, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
- Author
-
Meriglier, E., RIVOISY, C., Hessamfar, Mojgan, Bernard, N., AUREAU, I., LAPOIRIE, J., CONTIS, A., Sacher, F., SACRISTAN, B., LAHOUATI, M., PEDEBOSCQ, S., VANDENHENDE, M. A., Bouchet, Stéphane, Bonnet, Fabrice, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
immune system diseases ,virus diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie - Abstract
BACKGROUND: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection. OBJECTIVES: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. METHODS: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines. RESULTS: Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration. CONCLUSIONS: Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.
- Published
- 2021
- Full Text
- View/download PDF
26. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
- Author
-
Meriglier, Etienne, primary, Rivoisy, Claire, additional, Hessamfar, Mojgan, additional, Bernard, Noelle, additional, Aureau, Ines, additional, Lapoirie, Joelle, additional, Contis, Anne, additional, Sacher, Frédéric, additional, Sacristan, Benjamin, additional, Lahouati, Marin, additional, Pedeboscq, Stéphane, additional, Vandenhende, Marie-Anne, additional, Bouchet, Stéphane, additional, and Bonnet, Fabrice, additional
- Published
- 2020
- Full Text
- View/download PDF
27. ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)
- Author
-
Fleury, Hervé, primary, Caldato, Sabrina, additional, Recordon-Pinson, Patricia, additional, Thebault, Patricia, additional, Guidicelli, Gwenda-Line, additional, Hessamfar, Mojgan, additional, Morlat, Philippe, additional, Bonnet, Fabrice, additional, and Visentin, Jonathan, additional
- Published
- 2020
- Full Text
- View/download PDF
28. Additional file 1 of Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study
- Author
-
Barger, Diana, Hessamfar, Mojgan, Neau, Didier, Marc-Olivier Vareil, Lazaro, Estibaliz, Duffau, Pierre, Rouanes, Nicolas, Leleux, Olivier, Marec, Fabien Le, Erramouspe, Marie, Wittkop, Linda, Dabis, François, and Bonnet, Fabrice
- Subjects
Data_FILES - Abstract
Additional file 1.
- Published
- 2020
- Full Text
- View/download PDF
29. Additional file 2 of Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study
- Author
-
Barger, Diana, Hessamfar, Mojgan, Neau, Didier, Marc-Olivier Vareil, Lazaro, Estibaliz, Duffau, Pierre, Rouanes, Nicolas, Leleux, Olivier, Marec, Fabien Le, Erramouspe, Marie, Wittkop, Linda, Dabis, François, and Bonnet, Fabrice
- Subjects
Data_FILES - Abstract
Additional file 2.
- Published
- 2020
- Full Text
- View/download PDF
30. Incidence of sexually transmitted infections during pre-exposure prophylaxis for HIV: a worrying outcome at 2 years!
- Author
-
Ducours, Maïlys, primary, Alleman, Laure, additional, Puges, Mathilde, additional, Deborde, Matthieu, additional, Hessamfar, Mojgan, additional, Le-Marec, Fabien, additional, Dabis, François, additional, Pereyre, Sabine, additional, Bébéar, Cécile, additional, Descaux, Arnaud, additional, and Cazanave, Charles, additional
- Published
- 2019
- Full Text
- View/download PDF
31. Elvitegravir–Cobicistat–Emtricitabine–Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
- Author
-
Gantner, Pierre, Hessamfar, Mojgan, Souala, Mohamed Faouzi, Valin, Nadia, Simon, Anne, Ajana, Faiza, Bouvet, Elisabeth, Rouveix, Elisabeth, Cotte, Laurent, Bani-Sadr, Firouzé, Hustache-Mathieu, Laurent, Lebrette, Marie-Gisèle, Truchetet, François, Galempoix, Jean-Marie, Piroth, Lionel, Pellissier, Gérard, Muret, Patrice, Rey, David, and Group, E/C/F/TAF PEP Study
- Subjects
- *
HIV prevention , *HIV infection risk factors , *SEXUALLY transmitted disease diagnosis , *COMBINATION drug therapy , *CLINICAL trials , *CONFIDENCE intervals , *DRUGS , *HIV infections , *PATIENT compliance , *QUALITY of life , *RESEARCH funding , *ANTI-HIV agents - Abstract
We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. Clinical Trials Registration NCT02998320. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe
- Author
-
Monge, Susana, Jarrin, Inma, Pantazis, Nikos, Mocroft, Amanda, Sabin, Caroline, Touloumi, Giota, van Sighem, Ard, Abgrall, Sophie, Dray-Spira, Rosemary, Spire, Bruno, Castagna, Antonella, Mussini, Cristina, Zangerle, Robert, Hessamfar, Mojgan Bonarek M., Anderson, Jane, Hamouda, Osamah, Ehren, Kathrin, Obel, Niels, Kirk, Ole, de Monteynard, Laure Amélie, Antinori, Andrea, Girardi, Enrico, Saracino, Annalisa, Calmy, Alexandra, De Wit, Stéphane, Wittkop, Linda, Bucher, Heiner H.C., Montoliu, Alexandra, Raben, Dorthe, Prins, Maria, Meyer, Laurence, Chene, Geneviève, Burns, Fiona, del Amo, Julia, Monge, Susana, Jarrin, Inma, Pantazis, Nikos, Mocroft, Amanda, Sabin, Caroline, Touloumi, Giota, van Sighem, Ard, Abgrall, Sophie, Dray-Spira, Rosemary, Spire, Bruno, Castagna, Antonella, Mussini, Cristina, Zangerle, Robert, Hessamfar, Mojgan Bonarek M., Anderson, Jane, Hamouda, Osamah, Ehren, Kathrin, Obel, Niels, Kirk, Ole, de Monteynard, Laure Amélie, Antinori, Andrea, Girardi, Enrico, Saracino, Annalisa, Calmy, Alexandra, De Wit, Stéphane, Wittkop, Linda, Bucher, Heiner H.C., Montoliu, Alexandra, Raben, Dorthe, Prins, Maria, Meyer, Laurence, Chene, Geneviève, Burns, Fiona, and del Amo, Julia
- Abstract
Background: We evaluate differences in timing of cART (combined antiretroviral treatment) initiation by geographical origin in male and female HIV-positive patients in the Collaboration of Observational HIV Epidemiological Research Europe, a large European Collaboration of HIV Cohorts. Methods: We included individuals recruited in Western Europe between January 1997 and March 2013, with known geographical origin and at least 1 CD4þ cell count measurement while cART-naive. Timing of cART was assessed through modified time-to-event methods, in which a scale of CD4þ cell counts was used instead of time, with cART being the outcome. We estimated the median CD4þ cell count at cART initiation (estimated CD4þ levels at which the probability of having started cART is 50%) using Kaplan-Meier and adjusted hazard ratios of cART initiation using Cox regression. Results: Of 151 674 individuals, 110 592 (72.9%) were men. Median (95% confidence interval) CD4þ cell count falls far below 250 cells/ml in all groups and was lowest in sub-Saharan African [SSA: 161 (158-167)], Caribbean men [161 (150-174)] and in Asian women [Asian Continent and Oceania: 185 (165-197)]. Among men, the adjusted probability of cART initiation was lower in migrants compared with natives, but differences depended on initial CD4þ cell count. For example, in the group with more than 500 CD4þ at recruitment, they were 45% (36-53%), 30% (17-40%) and 25% (19-30%) lower for Caribbean, Eastern European and SSA men, respectively. In women, no meaningful differences were observed between natives and most migrant groups. However, SSA women had a 31% (24-38%) higher probability of cART initiation when recruited at a CD4þ more than 500 cells/ml and 9% (4-14%) lower when recruited at CD4þ less than 100 cells/ml. Conclusion: Most migrant men initiate cART at lower CD4þ cell count than natives, whereas this does not hold for migrant women., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2017
33. CAUSES OF DEATH AMONG ADULTS WITH HIV ON ART IN EUROPE AND NORTH AMERICA: 1996-2019.
- Author
-
Trickey, Adam, McGinnis, Kathleen, Gill, M. John, Abgrall, Sophie, Berenguer, Juan, Wyen, Christoph, Hessamfar, Mojgan, Reiss, Peter, Zhang, Lei, Ingle, Suzanne M., and Sterne, Jonathan Ac
- Published
- 2023
34. Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014
- Author
-
Cazanave, Charles, primary, Reigadas, Sandrine, additional, Mazubert, Cyril, additional, Bellecave, Pantxika, additional, Hessamfar, Mojgan, additional, Le Marec, Fabien, additional, Lazaro, Estibaliz, additional, Peytavin, Gilles, additional, Bruyand, Mathias, additional, Fleury, Hervé, additional, Dabis, François, additional, and Neau, Didier, additional
- Published
- 2015
- Full Text
- View/download PDF
35. Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients
- Author
-
Frulio, Nora, primary, Trillaud, Hervé, additional, Perez, Paul, additional, Asselineau, Julien, additional, Vandenhende, Marianne, additional, Hessamfar, Mojgan, additional, Bonnet, Fabrice, additional, Maire, Florent, additional, Delaune, Jean, additional, De Ledinghen, Victor, additional, and Morlat, Philippe, additional
- Published
- 2014
- Full Text
- View/download PDF
36. Chronic Viral Hepatitis Is Associated With Low Bone Mineral Density in HIV-Infected Patients, ANRS CO 3 Aquitaine Cohort
- Author
-
Lawson-Ayayi, Sylvie, primary, Cazanave, Charles, additional, Kpozehouen, Alphonse, additional, Barthe, Nicole, additional, Mehsen, Nadia, additional, Hessamfar, Mojgan, additional, Dupon, Michel, additional, Dabis, François, additional, and Neau, Didier, additional
- Published
- 2013
- Full Text
- View/download PDF
37. High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
- Author
-
Bell, Elisabeth Carolle Ngo, Vandenhende, Marie-Anne, Caldato, Sabrina, Saunier, Aurélie, Bellecave, Pantxika, Tumiotto, Camille, Avettand-Fenoel, Véronique, Hessamfar, Mojgan, Morlat, Philippe, Bonnet, Fabrice, and Ngo Bell, Elisabeth Carolle
- Subjects
EMTRICITABINE-tenofovir ,HIV-positive persons ,INTEGRASE inhibitors ,GENETIC mutation ,GENETIC polymorphisms ,THERAPEUTICS - Abstract
The article presents case series of acute primary HIV infection patient to demonstrate high decay of blood HIV reservoir after administration of tenofovir/emtricitabine/elvitegravir/cobicistat. It states that efficacy of integrase strand transfer inhibitor (INSTI) is affected by natural polymorphism of the integrase gene varies and minor mutations.
- Published
- 2017
- Full Text
- View/download PDF
38. Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Acquitaine Cohort.
- Author
-
Hessamfar, Mojgan, Colin, Céline, Bruyand, Mathias, Decoin, Madeleine, Bonnet, Fabrice, Mercié, Patrick, Neau, Didier, Cazanave, Charles, Pellegrin, Jean-Luc, Dabis, François, Morlat, Philippe, and Chêne, Geneviève
- Subjects
- *
HIV-positive persons , *ANTIRETROVIRAL agents , *SEX factors in disease , *HOSPITAL care , *COHORT analysis , *CARDIOVASCULAR diseases risk factors - Abstract
Objective: To describe trends and determinants of severe morbidity in HIV-infected women and men. Design: A French prospective cohort of HIV-infected patients of both sexes and all transmission categories. Methods: We used hospital admission data from January 2000 to December 2008. A severe morbid event (SME) was defined as a clinical event requiring hospitalization for ≥48 h, several events could be reported during hospitalization. Yearly incidence rates of SME were estimated and compared using Generalized Estimating Equations. Results: Among 4,987 patients (27% women), followed for a median of 8.7 years, 1,473 (30%) were hospitalized (3,049 hospitalizations for 5,963 SME). The yearly incidence rate of hospitalization decreased in men, from 155 in 2000 to 80/1,000 person-years (PY) in 2008 and in women, from 125 to 71/1,000 PY, (p<0.001). This trend was observed for all SME except for hepatic events, stable in men (15 to 13/1,000 PY) and increasing in women (2.5 to 11.5), cardiovascular events increasing in men (6 to 10/1,000 PY) and in women (6 to 14) and non-AIDS non-hepatic malignancies increasing in men (4 to 7/1,000 PY) and stable in women (2.5). Intraveneous drug users, age >50 years, HIV RNA >10,000 copies, CD4 <500/mm3, AIDS stage, hepatitis C co-infection and cardiovascular risk factors (diabetes, high blood pressure, and tobacco use) were associated with SME. Conclusions: HIV-infected individuals in care in France require less and less frequently hospitalization. Women are now presenting with severe hepatic and cardio-vascular events. Disparities in SME between men and women are primarily explained by different exposure patterns to risk factors. Women should be targeted to benefit cardiovascular prevention policies as well as men. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.
- Author
-
Mendes Luz, Paula, Bruyand, Mathias, Ribeiro, Sayonara, Bonnet, Fabrice, Ismério Moreira, Ronaldo, Hessamfar, Mojgan, Perreira Campos, Dayse, Greib, Carine, Cazanave, Charles, Gonçalves Veloso, Valdilea, Dabis, François, Grinsztejn, Beatriz, and Chêne, Geneviève
- Subjects
AIDS diagnosis ,MEDICAL care of HIV-positive persons ,HIGHLY active antiretroviral therapy ,CANCER chemotherapy ,DRUG withdrawal symptoms - Abstract
Background In high-income settings, the spectrum of morbidity and mortality experienced by Human Immunodeficiency Virus (HIV)-infected individuals receiving combination antiretroviral therapy (cART) has switched from predominantly AIDS-related to non-AIDS-related conditions. In the context of universal access to care, we evaluated whether that shift would apply in Brazil, a middle-income country with universal access to treatment, as compared to France. Methods Two hospital-based cohorts of HIV-infected individuals were used for this analysis: the ANRS CO3 Acquitaine Cohort in South Western France and the Evandro Chagas Research Institute (IPEC) Cohort of the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. Severe morbid events (AIDS- and non-AIDS-related) were defined as all clinical diagnoses associated with a hospitalization of ≥48 hours. Trends in the incidence rate of events and their determinants were estimated while adjusting for within-subject correlation using generalized estimating equations models with an auto-regressive correlation structure and robust standard errors. Result Between January 2000 and December 2008, 7812 adult patients were followed for a total of 41,668 person-years (PY) of follow-up. Throughout the study period, 90% of the patients were treated with cART. The annual incidence rate of AIDS and non-AIDS events, and of deaths significantly decreased over the years, from 6.2, 21.1, and 1.9 AIDS, non-AIDS events, and deaths per 100 PY in 2000 to 4.3, 14.9, and 1.5/100 PY in 2008. The annual incidence rates of non-AIDS events surpassed that of AIDS-events during the entire study period. High CD4 cell counts were associated with a lower incidence rate of AIDS and non- AIDS events as well as with lower rates of specific non-AIDS events, such as bacterial, hepatic, viral, neurological, and cardiovascular conditions. Adjusted analysis showed that severe morbidity was associated with lower CD4 counts and higher plasma HIV RNAs but not with setting (IPEC versus Acquitaine). Conclusions As information on severe morbidities for HIV-infected patients remain scarce, data on hospitalizations are valuable to identify priorities for case management and to improve the quality of life of patients with a chronic disease requiring life-long treatment. Immune restoration is highly effective in reducing AIDS and non-AIDS severe morbid events irrespective of the setting. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
40. Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort.
- Author
-
Wittkop, Linda, Bitard, Juliette, Lazaro, Estibaliz, Neau, Didier, Bonnet, Fabrice, Mercie, Patrick, Dupon, Michel, Hessamfar, Mojgan, Ventura, Michel, Malvy, Denis, Dabis, François, Pellegrin, Jean-Luc, Moreau, Jean-François, Thiébaut, Rodolphe, and Pellegrin, Isabelle
- Subjects
THERAPEUTICS ,HIV infections ,CYTOMEGALOVIRUSES ,IMMUNE response ,ANTIGENS ,ANTIRETROVIRAL agents ,GENE expression ,ENZYME-linked immunosorbent assay ,VIROLOGY ,CHROMOSOMAL translocation ,IMMUNOSUPPRESSION - Abstract
We evaluated the impact of cytomegalovirus (CMV)–induced immune responses, autoimmune-induced immune responses, and microbial translocation on immune activation in 191 human immunodeficiency virus type 1–infected patients from the ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt of combination antiretroviral therapy (cART). HLA-DR+/CD38+ expression was 16.8% among CD8+ T cells. Independent of age, CD4+ T-cell count, 16S ribosomal DNA load, and regulatory T-cell count, positive results of Quantiferon CMV analysis (P = .02), positive results of CMV-pp65 enzyme-linked immunosorbent spot analysis (P = .01), positive results of CMV-pp65–specific CD8+ T-cell analysis (P = .05), and CMV seropositivity (P = .01) were associated with a higher percentage of CD8+ T cells that expressed HLA-DR+/CD38+. Autoimmune response and microbial translocation were not associated with immune activation. Therefore, the CMV-induced immune response seems to be associated with chronic immune activation in cART recipients with sustained virological suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2013
41. Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US
- Author
-
Jarrin, Inma, Moreno, Santiago, Ingle, Sue, May, Margaret T, Sterling, Timothy R, Justice, Amy, Bickel, Markus, Crane, Heidi, Mugavero, Michael J, De Wolf, Frank, Jung, Norma, Cescon, Angela, Garcia, Isabel, Elzi, Luigia, Arminio, Antonella d, Krause, Murielle Mary, Smith, Colette, Guest, Jodie, Hessamfar, Mojgan, Gill, John, Sterne, Jonathan AC, and del Amo, Julia
- Abstract
Background Here, we aimed to evaluate regional differences in all-cause, AIDS- and non-AIDS-related mortality in HIV-positive men and women started on combination antiretroviral therapy (cART) in Europe, Canada and the US.Methods The ART Cohort Collaboration (ART-CC) combines 19 cohorts of individuals started on cART in Europe and North America (NA). We analysed patients infected via injecting drug use (IDU) or heterosexual sex using Cox proportional hazards models.Results A total of 32,443 European (45.9% women), 1,162 (32.5% women) Canadian and 2,721 (15.5% women) US patients were included. In Europe and NA, women were younger, more likely to have acquired HIV heterosexually, be AIDS-free and have higher CD4+T-cell counts and lower HIV-1 RNA at baseline. European women had lower rates of all-cause (adjusted hazard ratio: 0.76; 95% CI 0.68, 0.84) and non-AIDS mortality (0.67; 0.57, 0.78) than men, but AIDS-mortality rates were similar (0.90; 0.75, 1.09). Women had lower mortality due to non-AIDS infections (0.6 versus 1.3 per 1,000 person-years), liver diseases (0.4 versus 1.7), non-AIDS malignancies (0.6 versus 2.0) and cardiovascular diseases (0.6 versus 1.0). Between-sex differences in all-cause mortality were larger in heterosexuals (0.70; 0.61, 0.80) than in IDU (0.88; 0.73, 1.05; interaction P-value =0.043). No sex differences in all-cause mortality were found in Canada (hazard ratio women 1.13; 0.82, 1.56) or US (hazard ratio women 1.12; 0.79, 1.58).Conclusions The increasing importance of non-AIDS mortality is leading to emergent sex differences among HIV-positive patients in Europe, as in the general population. Despite the better clinical characteristics at cART initiation, women in NA had similar mortality to men.
- Published
- 2015
- Full Text
- View/download PDF
42. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.
- Author
-
Luz, Paula Mendes, Bruyand, Mathias, Ribeiro, Sayonara, Bonnet, Fabrice, Moreira, Ronaldo Ismério, Hessamfar, Mojgan, Campos, Dayse Perreira, Greib, Carine, Cazanave, Charles, Veloso, Valdilea Gonçalves, Dabis, François, Grinsztejn, Beatriz, Chêne, Geneviève, and IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group
- Abstract
Background: In high-income settings, the spectrum of morbidity and mortality experienced by Human Immunodeficiency Virus (HIV)-infected individuals receiving combination antiretroviral therapy (cART) has switched from predominantly AIDS-related to non-AIDS-related conditions. In the context of universal access to care, we evaluated whether that shift would apply in Brazil, a middle-income country with universal access to treatment, as compared to France.Methods: Two hospital-based cohorts of HIV-infected individuals were used for this analysis: the ANRS CO3 Aquitaine Cohort in South Western France and the Evandro Chagas Research Institute (IPEC) Cohort of the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. Severe morbid events (AIDS- and non-AIDS-related) were defined as all clinical diagnoses associated with a hospitalization of ≥48 hours. Trends in the incidence rate of events and their determinants were estimated while adjusting for within-subject correlation using generalized estimating equations models with an auto-regressive correlation structure and robust standard errors.Result: Between January 2000 and December 2008, 7812 adult patients were followed for a total of 41,668 person-years (PY) of follow-up. Throughout the study period, 90% of the patients were treated with cART. The annual incidence rate of AIDS and non-AIDS events, and of deaths significantly decreased over the years, from 6.2, 21.1, and 1.9 AIDS, non-AIDS events, and deaths per 100 PY in 2000 to 4.3, 14.9, and 1.5/100 PY in 2008. The annual incidence rates of non-AIDS events surpassed that of AIDS-events during the entire study period. High CD4 cell counts were associated with a lower incidence rate of AIDS and non-AIDS events as well as with lower rates of specific non-AIDS events, such as bacterial, hepatic, viral, neurological, and cardiovascular conditions. Adjusted analysis showed that severe morbidity was associated with lower CD4 counts and higher plasma HIV RNAs but not with setting (IPEC versus Aquitaine).Conclusions: As information on severe morbidities for HIV-infected patients remain scarce, data on hospitalizations are valuable to identify priorities for case management and to improve the quality of life of patients with a chronic disease requiring life-long treatment. Immune restoration is highly effective in reducing AIDS and non-AIDS severe morbid events irrespective of the setting. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
43. Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
- Author
-
Trickey A, Ingle SM, Boyd A, Gill MJ, Grabar S, Jarrin I, Obel N, Touloumi G, Zangerle R, Rauch A, Rentsch CT, Satre DD, Silverberg MJ, Bonnet F, Guest J, Burkholder G, Crane H, Teira R, Berenguer J, Wyen C, Abgrall S, Hessamfar M, Reiss P, d'Arminio Monforte A, McGinnis KA, Sterne JAC, and Wittkop L
- Subjects
- Adult, Humans, Hepacivirus, Cause of Death, Cohort Studies, Coinfection epidemiology, Coinfection complications, Hepatitis C complications, Hepatitis C epidemiology, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology
- Abstract
Among persons with HIV (PWH), higher alcohol use and having hepatitis C virus (HCV) are separately associated with increased morbidity and mortality. We investigated whether the association between alcohol use and mortality among PWH is modified by HCV. Data were combined from European and North American cohorts of adult PWH who started antiretroviral therapy (ART). Self-reported alcohol use data, collected in diverse ways between cohorts, were converted to grams/day. Eligible PWH started ART during 2001-2017 and were followed from ART initiation for mortality. Interactions between the associations of baseline alcohol use (0, 0.1-20.0, >20.0 g/day) and HCV status were assessed using multivariable Cox models. Of 58,769 PWH, 29,711 (51%), 23,974 (41%) and 5084 (9%) self-reported alcohol use of 0 g/day, 0.1-20.0 g/day, and > 20.0 g/day, respectively, and 4799 (8%) had HCV at baseline. There were 844 deaths in 37,729 person-years and 2755 deaths in 443,121 person-years among those with and without HCV, respectively. Among PWH without HCV, adjusted hazard ratios (aHRs) for mortality were 1.18 (95% CI: 1.08-1.29) for 0.0 g/day and 1.84 (1.62-2.09) for >20.0 g/day compared with 0.1-20.0 g/day. This J-shaped pattern was absent among those with HCV: aHRs were 1.00 (0.86-1.17) for 0.0 g/day and 1.64 (1.33-2.02) for >20.0 g/day compared with 0.1-20.0 g/day (interaction p < .001). Among PWH without HCV, mortality was higher in both non-drinkers and heavy drinkers compared with moderate alcohol drinkers. Among those with HCV, mortality was higher in heavy drinkers but not non-drinkers, potentially due to differing reasons for not drinking (e.g. illness) between those with and without HCV., (© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
44. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort.
- Author
-
Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehsen N, Hessamfar M, Dupon M, Dabis F, and Neau D
- Subjects
- Adult, Chronic Disease, Cohort Studies, Female, Humans, Male, Middle Aged, Bone Density, HIV Infections physiopathology, Hepatitis, Viral, Human physiopathology
- Abstract
Background: High prevalence rates of low bone mineral density (BMD) have been reported in people living with HIV infection. We aimed to investigate the association of chronic viral hepatitis with low BMD in HIV-infected patients., Methods: A hospital-based cohort of HIV-infected patients was screened for hepatitis B and C coinfection. BMD was measured by dual energy x-ray absorptiometry. T-score was used to define bone status according to the World Health Organization's classification; moreover, each observed BMD value was compared with reference to an average person of the same age and gender as a Z-score <-2.0 allow the diagnosis of patients having less bone mass and/or losing bone material more rapidly than expected. A polytomial logistic regression was performed by gender to investigate the association between chronic viral hepatitis and low BMD (osteopenia and osteoporosis) in HIV-infected patients., Results: A total of 626 patients (166 females of whom 52 postmenopausal) were recruited: 357 HIV monoinfected, and 269 HIV-coinfected with chronic viral hepatitis, among whom 61 with a diagnosis of cirrhosis. Osteopenia was present in 320 patients (51.1%) and osteoporosis in 187 (29.9%). After adjustment, osteoporosis was associated with older age and low body mass index in both genders. The association between chronic viral hepatitis B or C and osteoporosis was found in women only (odds ratio: 19.0; P value: 0.047)., Conclusions: We found a high prevalence of low BMD overall, but chronic viral hepatitis was independently associated with osteoporosis only in female participants. Our data confirm the need of BMD evaluations for patients living with HIV.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.